Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun, Chaowei Ren, Ying Kong, Hui Zhong, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou, Xing Qiu, Haifan Lin, Xiaoling Song, Xiaobao Yang, Biao Jiang
Topics & Concepts
Anaplastic lymphoma kinaseCancer researchALK inhibitorChemistryCrizotinibGrowth inhibitionCell cultureCell growthLung cancerCancer cellCancerDrug resistanceBiologyInternal medicineMedicineBiochemistryGeneticsMalignant pleural effusionProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisUbiquitin and proteasome pathways